Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides (NNVC) has registered its Phase II trial of NV-387 oral gummies for Ebola treatment in the Pan African Clinical Trials Registry.
The trial, led by principal investigator Prof. Patrick de Marie Chimusa Katoto in the Democratic Republic of Congo, carries ID PACTR202608748555077 and has received regulatory approval from ACOREP to begin. Drug product has been shipped and received at the Ituri province trial site, and first Ebola patient dosing is expected within one to two weeks, subject to outbreak-related constraints. The adaptive, multi-centre Phase IIA/IIB design starts with a single-arm safety and dose run-in, followed by a randomised, controlled, open-label efficacy evaluation. NV-387 is an orally delivered, broad‑spectrum antiviral being evaluated amid a rapidly expanding Bundibugyo ebolavirus outbreak.
NanoViricides (NYSE American: NNVC) reported progress in its measles treatment program, highlighting broad-spectrum antiviral candidate NV-387. NV-387 has shown strong in vivo activity against lethal measles infection in a humanized animal model and is being advanced toward a Phase II clinical trial under an IND process with the US FDA.
According to NanoViricides, NV-387 has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug (RPDD) designation from the FDA for measles, making the company eligible for incentives such as tax credits, user-fee exemptions, potential seven-year market exclusivity, and a potential Priority Review Voucher (PRV), which the company notes have recently sold for about $195 million.
NanoViricides (NYSE American: NNVC) reported that local regulator ACOREP in the Democratic Republic of Congo has approved a Phase II clinical trial of NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak and other Ebola viruses. Professor Patrick Katoto of the Catholic University of Bukavu will serve as principal investigator, with Om Sai Clinical Research as CRO.
According to the company, trial drug product is already in DRC, originally shipped for an impending Phase II Mpox trial, enabling rapid start of Ebola patient dosing, anticipated within weeks, subject to outbreak-related constraints. The outbreak has reached 4,945 confirmed cases and 2,325 deaths in DRC as of August 14, 2026, with a crude fatality rate of 46%.
NanoViricides (NYSE American: NNVC) reported that regulator ACOREP in the Democratic Republic of Congo has approved a Phase II clinical trial of its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak and other Ebola viruses.
According to the company, Om Sai Clinical Research (India) will serve as CRO, working with a local principal investigator and a regional university. Sufficient NV-387 oral gummies are already positioned in DRC, originally shipped for a Phase II Mpox trial and now available to support the Ebola study upon approval. The company describes NV-387 as a broad-spectrum, orally delivered antiviral mimicking a host-cell feature used by many viruses, with room-temperature stability and dissolving gummies that do not require water, which may be advantageous in resource-limited epidemic settings.
NanoViricides (NYSE American: NNVC) reported that it is awaiting regulatory approval from the DR Congo agency ACOREP for a Phase II clinical trial of NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company stated it has already completed financing that it believes is sufficient to cover the additional expenses of this anticipated trial.
According to NanoViricides, NV-387 is a broad-spectrum antiviral and, to its knowledge, the only orally active Ebola treatment candidate currently under consideration for clinical testing. A contract research organization, Om Sai Clinical Research, and a local principal investigator in the affected region have submitted the trial application, and drug product supply is already in DRC. Om Sai is also leading a Phase II trial of NV-387 oral gummies for Mpox in DRC, positioning logistics and infrastructure that may support the proposed Ebola study.
NanoViricides (NYSE American: NNVC) entered a securities purchase agreement with a single fundamental institutional investor for a registered direct offering of 2,516,339 common shares (or pre-funded warrants in lieu) plus accompanying warrants to buy 2,516,339 common shares, for expected gross proceeds of approximately US$3.8 million.
Each whole warrant is exercisable at US$1.75 per share and will expire five and a half years from issuance. Closing is expected on or about July 27, 2026, subject to customary conditions. According to NanoViricides, the securities are being issued under an effective Form S-3 shelf registration declared effective on June 15, 2026, with a prospectus supplement to be filed. The company also highlights its clinical-stage broad-spectrum antiviral NV-387, which has US FDA Orphan Drug Designation that could provide seven years’ market exclusivity, tax credits, and fee exemptions upon approval.
NanoViricides (NYSE American: NNVC) has applied to the Democratic Republic of Congo’s regulatory agency ACOREP for approval to begin a Phase II clinical trial of its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company has engaged Om Sai Clinical Research as CRO, leveraging its existing NV-387 Phase II mpox trial infrastructure in DRC, and says sufficient NV-387 drug product is already on the ground to start the Ebola study once approved.
NanoViricides describes NV-387 as a broad‑spectrum, orally delivered antiviral designed to mimic host cell features such as heparan sulfate proteoglycans that many viruses use to infect cells. According to the company, NV-387 showed superiority to remdesivir in a lethal animal model and could have potential against multiple filoviruses if clinical trials demonstrate safety and efficacy.
NanoViricides (NYSE American: NNVC) reported National Ethics Committee approval in the Democratic Republic of Congo for a planned Phase II clinical trial of its oral antiviral candidate NV-387 gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing a clinical trial application to the DRC regulator ACOREP, leveraging documents previously used for an approved Phase II Mpox trial of the same drug in DRC. NV-387 oral gummies have already been shipped to DRC for the Mpox program, providing on-site drug supply for the proposed Ebola study. According to NanoViricides, NV-387 is a broad-spectrum, orally administered antiviral designed to target host-cell features used by many viruses, and is believed by the company to have potential activity against multiple ebolaviruses and other filoviruses.
NanoViricides (NYSE American: NNVC) announced that Noble Capital Markets initiated independent research coverage on July 6, 2026, with an “Outperform” rating and a $6.00 target price. The report reviews current and longer-term antiviral programs.
Separately, a June 29, 2026 fireside chat with President Dr. Anil Diwan on the company’s broad-spectrum antiviral technology, Orphan Drug Designation for measles-related work, and the lead candidate NV-387—now being advanced toward Phase II trials—was published by StockInvestor Daily and is available on the company’s website.
NanoViricides (NYSE American: NNVC) reports progress toward a Phase II clinical trial of NV-387 Oral Gummies for treating Bundibugyo ebolavirus in DR Congo. A trial proposal has been approved by the DRC Pillar Committee, and NV-387 is already cleared by ACOREP for a Phase II Mpox trial with drug product shipped to DRC.
NV-387 is described as a broad-spectrum, orally delivered antiviral that mimics host-cell HSPG, aiming to offer an alternative to infusion-based Ebola treatments, pending ethics and regulatory approvals and demonstration of clinical effectiveness.